Trials / Active Not Recruiting
Active Not RecruitingNCT07238322
[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes
An Assessment of the Efficacy of Floretyrosine F 18 ([18F]FET) Positron Emission Tomography (PET) for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 400 (estimated)
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
This study is designed to prospectively analyze \[18F\]FET PET image data obtained retrospectively in the routine clinical care of glioma patients. The study will analyse the data from participants with grade (1-4) glioma after primary treatment according to local clinical practice and with suspicion of progression/recurrence on magnetic resonance imaging (MRI).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | 18F(FET)PET | Imaging as part of routine care |
Timeline
- Start date
- 2025-09-22
- Primary completion
- 2026-02-23
- Completion
- 2026-02-23
- First posted
- 2025-11-20
- Last updated
- 2026-02-20
Locations
4 sites across 3 countries: United States, Germany, Netherlands
Source: ClinicalTrials.gov record NCT07238322. Inclusion in this directory is not an endorsement.